Form 4: Definium CEO Sells Shares for Tax Obligations

Definium Therapeutics CEO Robert Barrow sold 24,431 common shares on March 25, 2026, to cover tax obligations from vested restricted stock units.

Summary

• Robert Barrow, CEO, Director, and 10% Owner of Definium Therapeutics, Inc. (DFTX), reported a sale of common shares.
• On March 25, 2026, Mr. Barrow disposed of 24,431 common shares at a weighted average price of $18.47 per share.
• The shares were sold in multiple transactions ranging from $18.36 to $18.80.
• The sale was conducted to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units.
• This transaction was executed pursuant to a Rule 10b5-1 plan adopted on June 15, 2022.
• Following the transaction, Mr. Barrow beneficially owns 752,454 common shares directly.
• The reported amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executives managing vested equity awards and tax liabilities under a pre-established plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly 'sell-to-cover' transactions for tax obligations, are common and generally not indicative of management's sentiment about the company's future prospects, especially when executed under a pre-arranged 10b5-1 plan.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of insider ownership but is a routine event for tax purposes and not indicative of a change in confidence.
• Employees: The transaction is specific to executive compensation and does not directly impact the broader employee base.

Key Dates

Recommendation

The transaction is a routine 'sell-to-cover' by the CEO to satisfy tax obligations from vested restricted stock units, executed under a pre-arranged 10b5-1 plan. This type of insider sale is generally not interpreted as a lack of confidence in the company's future and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Definium Therapeutics, DFTX, Robert Barrow, Insider Trading, Form 4, Stock Sale, CEO, Restricted Stock Units, 10b5-1 Plan, Tax Obligations